|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:CEO
|
gptkb:Chris_Cargill
|
|
gptkbp:collaboratesWith
|
gptkb:Pfizer
gptkb:AstraZeneca
gptkb:Genentech
gptkb:Novartis
gptkb:Takeda_Pharmaceutical_Company
|
|
gptkbp:country
|
gptkb:Japan
|
|
gptkbp:focusesOn
|
immunology
oncology
drug discovery
drug development
rare diseases
neurological diseases
|
|
gptkbp:founded
|
1990
|
|
gptkbp:founder
|
gptkb:Shinichi_Tamura
|
|
gptkbp:headquarters_location
|
gptkb:Tokyo
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Sosei Group Corporation
|
|
gptkbp:industry
|
gptkb:biotechnology
pharmaceuticals
|
|
gptkbp:listedOn
|
Mothers section of Tokyo Stock Exchange
|
|
gptkbp:numberOfEmployees
|
over 150
|
|
gptkbp:parentCompany
|
gptkb:Heptares_Therapeutics
|
|
gptkbp:servesArea
|
worldwide
|
|
gptkbp:specializesIn
|
G protein-coupled receptor (GPCR) drug discovery
|
|
gptkbp:stockExchange
|
gptkb:Tokyo_Stock_Exchange
|
|
gptkbp:stockSymbol
|
4565
|
|
gptkbp:subsidiary
|
gptkb:Heptares_Therapeutics
|
|
gptkbp:website
|
https://soseiheptares.com/
|
|
gptkbp:bfsParent
|
gptkb:Sosei_Heptares
|
|
gptkbp:bfsLayer
|
7
|